JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.

Long-term L-dopa treatment of Parkinson's disease can lose its effectiveness and cause development of motor complications such as dyskinesia. Furthermore, L-dopa therapy does not address the fundamental pathological process of dopaminergic neurodegeneration in Parkinson's disease. This prompts a search for an alternative or complementary therapy for Parkinson's disease to overcome these limitations. During the last 5 years, the adenosine A(2A) receptor has emerged as an attractive target for Parkinson's disease therapy, primarily because of its localized expression in striatum and motor enhancement function. Recent genetic and pharmacological studies indicate that A(2A) receptor antagonists also offer neuroprotective effects and may possibly modify chronic L-dopa-induced maladaptive responses in animal models of Parkinson's disease. This review summarizes multiple potential benefits of the A(2A) receptor blockade in treating the motor symptoms as well as the underlying dopaminergic neurodegeneration of Parkinson's disease.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app